Embryo quality

Embryo quality is the ability of an embryo to perform successfully in terms of conferring a high pregnancy rate and/or resulting in a healthy person. Embryo profiling is the estimation of embryo quality by qualification and/or quantification of various parameters. Estimations of embryo quality guides the choice in embryo selection in in vitro fertilization.

In general, embryo profiling for prediction of pregnancy rates focuses mainly on visual profiles and short-term biomarkers including expression of RNA and proteins, preferably in the surroundings of embryos to avoid any damage to them. On the other hand, embryo profiling for health prediction puts more focus on the genome, and where there is a risk of a genetic disorder it more often involves cell sampling from the embryo for preimplantation genetic diagnosis.

Prediction of pregnancy rates

Microscopy

Embryo quality is mainly evaluated by microscopy at certain time points using a morphological scoring system. This has shown to significantly improve pregnancy rates.[1]

Time-lapse microscopy is an expansion of microscopy wherein the morphology of embryos is studies over time. As of 2014, time-lapse microscopy for embryo quality assessment is emerging from the experimental stage to something with enough evidence for broader clinical use.[2][3] Studies using the EmbryoScope(tm) time-lapse incubator have used several indicators for embryo quality, such as direct cleavage from 1 to 3 cells,[4] as well as the initiation of compaction and start of blastulation.[5][6][7] Also, two-pronuclear zygotes (2PN) transitioning through 1PN or 3PN states tend to develop into poorer-quality embryos than those that constantly remain 2PN.[8]

Molecular analysis

Molecular analysis can be performed by taking one of the cells from an embryo. The analys can vary in extent from a single target biomarker to entire genomes, transcriptomes, proteomes and metabolomes. The results may be used to score embryos by comparing the patterns with ones that have previously been found among embryos in successful versus unsuccessful pregnancies:[9]

Transcriptome profiling

In transcriptome evaluation, gene expression profiling studies of human embryos are limited due to legal and ethical issues.[9]

Gene expression profiling of cumulus cells surrounding the oocyte and early embryo, or on granulosa cells, provides an alternative that does not involve sampling from the embryo itself.[9] Profiling of cumulus cells can give valuable information regarding the efficiency of an ovarian hyperstimulation protocol, and may indirectly predict oocyte aneuploidy, embryo development and pregnancy outcomes, without having to perform any invasive procedure directly in the embryo.[9]

In addition, microRNA (miRNA) and cell-free DNA (cfDNA) can be sampled from the vicinity of embryos, functioning as transcriptome-level-markers of embryo quality.[10]

Proteome profiling

Proteome profiling of embryos can indirectly be evaluated by sampling of proteins found in the vicinity of embryos, thereby providing a non-invasive method of embryo profiling.[9] Examples of protein markers evaluated in such profiling include CXCL13 and granulocyte-macrophage colony-stimulating factor, where lower protein amounts are associated with higher implantation rates.[9] The presence of soluble HLA-G might be considered as another parameter if a choice has to be made between embryos of equal visible quality.[1]

Another level of opportunity can be achieved by having the evaluation of the embryo profile tailored to the maternal status in regard to, for example health or immune status, potentially further detailed by similar profiling of the maternal genome, transcriptome, proteome and metabolome. Two examples of proteins that may be included in maternal profiling are endometrium-derived stathmin 1 and annexin A2, whose down- and up-regulation, respectively, are associated with higher rates of successful implantation.[9]

Genome profiling

A systematic review and meta-analysis of existing randomized controlled trials came to the result that there is no evidence of a beneficial effect of PGP as measured by live birth rate.[11] On the contrary, for women of advanced maternal age, PGP significantly lowers the live birth rate.[11] Technical drawbacks, such as the invasiveness of the biopsy, and chromosomal mosaicism are the major underlying factors for inefficacy of PGP.[11]

A major drawback of genomic profiling for embryo quality is that the results generally rely on the assessment of a single cell, PGP has inherent limitations as the tested cell may not be representative of the embryo because of mosaicism.[11]

When used for women of advanced maternal age and for patients with repetitive IVF failure, PGP is mainly carried out as a screening for detection of chromosomal abnormalities such as aneuploidy, reciprocal and Robertsonian translocations, and few cases for other abnormalities such as chromosomal inversions or deletions. The principle behind it is that, since it is known that numerical chromosomal abnormalities explain most of the cases of pregnancy loss, and a large proportion of the human embryos are aneuploid, the selective replacement of euploid embryos should increase the chances of a successful IVF treatment. Comprehensive chromosome analysis methods include array-comparative genomic hybridization (aCGH), quantitative PCR and SNP arrays.[9] Combined with single blastomere biopsy on day-3 embryos, aCGH is very robust with 2.9% of tested embryos with no results, and associated with low error rates (1.9%).[9]

In addition to screening for specific abnormalities, techniques are in development that can avail for up to full genome sequencing, from which genetic profiling can score the DNA patterns by comparing with ones that have previously been found among embryos in successful or unsuccessful pregnancies.[9]

Health prediction

The main method currently used to predict the health of a resultant person of an embryo is preimplantation genetic diagnosis (also called preimplantation genetic screening, preimplantation genetic profiling or PGP), in order to determine whether the resultant person will inherit a specific disease or not. On the other hand, a systematic review and meta-analysis of existing randomized controlled trials came to the result that there is no evidence of a beneficial effect of PGP as measured by live birth rate.[11] On the contrary, for women of advanced maternal age, PGP significantly lowers the live birth rate.[11] Technical drawbacks, such as the invasiveness of the biopsy, and chromosomal mosaicism are the major underlying factors for inefficacy of PGP.[11]

References

  1. 1 2 Rebmann, V.; Switala, M.; Eue, I.; Grosse-Wilde, H. (2010). "Soluble HLA-G is an independent factor for the prediction of pregnancy outcome after ART: A German multi-centre study". Human Reproduction 25 (7): 1691–1698. doi:10.1093/humrep/deq120. PMID 20488801.
  2. ↑ Kaser, D. J.; Racowsky, C. (2014). "Clinical outcomes following selection of human preimplantation embryos with time-lapse monitoring: a systematic review". Human Reproduction Update 20 (5): 617–631. doi:10.1093/humupd/dmu023. ISSN 1355-4786.
  3. ↑ Freour, T.; Basile, N.; Barriere, P.; Meseguer, M. (2014). "Systematic review on clinical outcomes following selection of human preimplantation embryos with time-lapse monitoring". Human Reproduction Update 21 (1): 153–154. doi:10.1093/humupd/dmu054. ISSN 1355-4786.
  4. ↑ Rubio, I.; Kuhlmann, R.; Agerholm, I.; Kirk, J.; Herrero, J.; Escribá, M. A. J.; Bellver, J.; Meseguer, M. (2012). "Limited implantation success of direct-cleaved human zygotes: A time-lapse study". Fertility and Sterility 98 (6): 1458–1463. doi:10.1016/j.fertnstert.2012.07.1135. PMID 22925687.
  5. ↑ Campbell, A.; Fishel, S.; Bowman, N.; Duffy, S.; Sedler, M.; Hickman, C. F. L. (2013). "Modelling a risk classification of aneuploidy in human embryos using non-invasive morphokinetics". Reproductive BioMedicine Online 26 (5): 477–485. doi:10.1016/j.rbmo.2013.02.006. PMID 23518033.
  6. ↑ Meseguer, M.; Herrero, J.; Tejera, A.; Hilligsøe, K. M.; Ramsing, N. B.; Remohí, J. (2011). "The use of morphokinetics as a predictor of embryo implantation". Human Reproduction 26 (10): 2658–2671. doi:10.1093/humrep/der256. PMID 21828117.
  7. ↑ Dal Canto, M.; Coticchio, G.; Mignini Renzini, M.; De Ponti, E.; Novara, P. V.; Brambillasca, F.; Comi, R.; Fadini, R. (2012). "Cleavage kinetics analysis of human embryos predicts development to blastocyst and implantation". Reproductive BioMedicine Online 25 (5): 474–480. doi:10.1016/j.rbmo.2012.07.016. PMID 22995750.
  8. ↑ Reichman, D. E.; Jackson, K. V.; Racowsky, C. (2010). "Incidence and development of zygotes exhibiting abnormal pronuclear disposition after identification of two pronuclei at the fertilization check". Fertility and Sterility 94 (3): 965–970. doi:10.1016/j.fertnstert.2009.04.018. PMID 19476942.
  9. 1 2 3 4 5 6 7 8 9 10 The Evian Annual Reproduction (EVAR) Workshop Group 2010; Fauser, B. C. J. M.; Diedrich, K.; Bouchard, P.; Domínguez, F.; Matzuk, M.; Franks, S.; Hamamah, S.; Simón, C.; Devroey, P.; Ezcurra, D.; Howles, C. M. (2011). "Contemporary genetic technologies and female reproduction". Human Reproduction Update 17 (6): 829–847. doi:10.1093/humupd/dmr033. PMC 3191938. PMID 21896560.
  10. ↑ Traver, S.; Assou, S.; Scalici, E.; Haouzi, D.; Al-Edani, T.; Belloc, S.; Hamamah, S. (2014). "Cell-free nucleic acids as non-invasive biomarkers of gynecological cancers, ovarian, endometrial and obstetric disorders and fetal aneuploidy". Human Reproduction Update 20 (6): 905–923. doi:10.1093/humupd/dmu031. ISSN 1355-4786.
  11. 1 2 3 4 5 6 7 Mastenbroek, S.; Twisk, M.; Van Der Veen, F.; Repping, S. (2011). "Preimplantation genetic screening: A systematic review and meta-analysis of RCTs". Human Reproduction Update 17 (4): 454–466. doi:10.1093/humupd/dmr003. PMID 21531751.
This article is issued from Wikipedia - version of the Monday, March 07, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.